Condition: Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms · Sponsor: Corcept Therapeutics
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
This description comes directly from the study's public registry record.
Corcept Therapeutics · 650-414-2314 · corceptstudy557@corcept.com
Always discuss trial participation with your own doctor first.
| 004 | Birmingham, Alabama, United States | Recruiting |
| 150 | Palo Alto, California, United States | Recruiting |
| 014 | San Francisco, California, United States | Recruiting |
| 544 | Fort Myers, Florida, United States | Recruiting |
| 335 | Miami Beach, Florida, United States | Recruiting |
| 543 | West Palm Beach, Florida, United States | Recruiting |
| 518 | Minneapolis, Minnesota, United States | Recruiting |
| 334 | Kansas City, Missouri, United States | Recruiting |
| 521 | St Louis, Missouri, United States | Recruiting |
| 292 | Albuquerque, New Mexico, United States | Recruiting |
| 304 | Centerville, Ohio, United States | Recruiting |
| 517 | Eugene, Oregon, United States | Recruiting |
+ 37 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06906341